The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Cilta-cel achieves deep and durable responses for R/R multiple myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, gives an update on the ongoing Phase Ib/II CARTITUDE-1 study (NCT03548207) investigating ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-targeting therapy for patients with relapsed/refractory (R/R) multiple myeloma. Combined results from the Ib and II portions of the study have found an overall response rate (ORR) of over 95% and a median progression-free survival (PFS) of 75% at 12.4 months. Dr Martin also discusses how patients have a significant improvement in quality of life. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding to institution: Sanofi, Janssen, AMGEN
Consultancy: GSK
